Ultragenyx Pharmaceutical Inc.
RARENASDAQHealthcare● Active
$21.59
$-0.32(-1.46%)
Market Cap$2.1B
P/E Ratio—
52W High$42.37
52W Low$18.29
Ultragenyx Pharmaceutical Inc.（RARE）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · RARE · 截至 2026-06-08
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.67B | $0.56B | $0.43B | $0.36B | $0.35B |
| Cost of Revenue | $0.11B | $0.08B | $0.05B | $0.03B | $0.02B |
| Gross Profit | $0.56B | $0.48B | $0.39B | $0.34B | $0.34B |
| Gross Margin %(computed) | 83.80% | 86.30% | 89.59% | 92.21% | 95.44% |
| Operating Expenses | |||||
| R&D Expenses | $0.75B | $0.70B | $0.65B | $0.71B | $0.50B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $1.10B | $1.02B | $0.96B | $0.98B | $0.72B |
| Operating Income | ($0.54B) | ($0.54B) | ($0.57B) | ($0.65B) | ($0.38B) |
| Operating Margin %(computed) | -79.49% | -95.67% | -131.08% | -178.60% | -108.63% |
| Interest Income | $0.03B | $0.04B | $0.03B | $0.01B | $0.00B |
| Interest Expense | $0.06B | $0.06B | $0.07B | $0.04B | $0.03B |
| Income Before Tax | ($0.57B) | ($0.57B) | ($0.61B) | ($0.70B) | ($0.45B) |
| Income Tax Expense | $0.00B | $0.00B | ($0.00B) | $0.01B | $0.00B |
| Net Income | ($0.57B) | ($0.57B) | ($0.61B) | ($0.71B) | ($0.45B) |
| Net Margin %(computed) | -85.44% | -101.60% | -139.70% | -194.71% | -129.20% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-5.83 | $-6.29 | $-8.25 | $-10.12 | $-6.70 |
| Wtd Avg Shares | 0.10B | 0.09B | 0.07B | 0.07B | 0.07B |
| EBITDA | ($0.50B) | ($0.47B) | ($0.52B) | ($0.64B) | ($0.41B) |
| EBITDA Margin %(computed) | -74.29% | -83.72% | -118.93% | -176.28% | -116.77% |
数据来源：Financial Modeling Prep · 最后更新：2026-06-08 · USD · B
深入了解Ultragenyx Pharmaceutical Inc.
关于Ultragenyx Pharmaceutical Inc.（RARE）损益表
Ultragenyx Pharmaceutical Inc.（RARE）损益表数据来源于SEC Form 10-K及10-Q申报文件。2025财年，RARE实现营收$0.67B，毛利润$0.56B（毛利率83.80%），净利润($0.57B)（净利率-85.44%）。
常见问题
RARE · 4 问Ultragenyx Pharmaceutical Inc.（RARE）2025财年营收为$0.67B，同比up20.1%。
RARE revenueRARE salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08